^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Oncofid-P (paclitaxel-hyaluronic acid conjugate)

Associations
Trials
Company:
Fidia Farmaceutici
Drug class:
Bcl2 inhibitor, Tubulin inhibitor
Related drugs:
Associations
Trials
7ms
A paclitaxel-hyaluronan conjugate (ONCOFID-P-B™) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment. (PubMed, J Exp Clin Cancer Res)
The clinical response to ONCOFID-P-B™ in bladder CIS likely relies on several components of the TME, and the combined evaluation of intra-tumoral macrophages density and CD44v6 expression is a potentially new predictive biomarker for patient response. Overall, our data allow to advance a potential rationale for combinatorial treatments targeting the immune infiltrate such as immune checkpoint inhibitors, to make bladder CIS more responsive to ONCOFID-P-B™ treatment.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • ICAM1 (Intercellular adhesion molecule 1)
|
CD44 expression
|
paclitaxel • Oncofid-P (paclitaxel-hyaluronic acid conjugate)
12ms
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) (clinicaltrials.gov)
P3, N=112, Recruiting, Fidia Farmaceutici s.p.a.
Trial completion date • Trial primary completion date
|
paclitaxel • Oncofid-P (paclitaxel-hyaluronic acid conjugate)
3years
Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start. (PubMed, Urol Oncol)
Oncofid-P-B is very safe, well tolerated and highly effective (75% CR) when administered weekly for up to 12 consecutive weeks (75% CR), with 40% CR still after 15 months from treatment start.
Clinical • Journal
|
CD44 (CD44 Molecule)
|
paclitaxel • Oncofid-P (paclitaxel-hyaluronic acid conjugate)
over3years
Simultaneous Targeting Tumor Cells and Cancer-Associated Fibroblasts with a Paclitaxel-Hyaluronan Bioconjugate: In Vitro Evaluation in Non-Melanoma Skin Cancer. (PubMed, Biomedicines)
Collectively, our data demonstrate that Onco-P20, exerting both a direct and an NHF-mediated indirect effect on carcinoma cells, is a candidate for an innovative therapy alternative to surgery for the treatment of NMSC.
Preclinical • Journal
|
CD44 (CD44 Molecule)
|
CD44 expression
|
paclitaxel • Oncofid-P (paclitaxel-hyaluronic acid conjugate)